# SS-31 Peptide

> SS-31 is elamipretide, a mitochondria-targeted tetrapeptide that binds cardiolipin and supports inner-membrane function, energy production, and cell protection.

Canonical: https://pepflow.app/peptides/ss-31/

The Mitochondrial Stabilizer

SS-31 is elamipretide, a mitochondria-targeted tetrapeptide designed to associate with cardiolipin and support mitochondrial inner-membrane function.

Mitochondrial aging  Mitochondrial support

Tier A

Evidence Strong

Safety Well-Studied

FDA status Approved

Last reviewed October 25, 2026 26 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is SS-31?

SS-31 is elamipretide, a mitochondria-targeted tetrapeptide designed to associate with cardiolipin and support mitochondrial inner-membrane function.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

As of September 19, 2025, FDA granted accelerated approval to elamipretide as Forzinity for Barth syndrome, making its regulatory status very different from most research-market mitochondrial peptides.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

That approval does not mean SS-31 is established for general anti-aging, athletic recovery, dry AMD, heart failure, or mitochondrial-wellness use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

## What SS-31 is investigated for

SS-31 evidence is grouped by practical use case and injectable and ophthalmic route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Barth syndrome Injectable 80% Strong

Barth syndrome has the clearest clinical-development evidence for SS-31/elamipretide.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/40816230/>)

#### Human evidence

Randomized and long-term extension data evaluate elamipretide in Barth syndrome.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/40816230/>)

#### Animal / mechanistic evidence

Tafazzin knockdown mouse work supports the Barth mitochondrial mechanism.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/38871974/>)

### ### Primary mitochondrial myopathy and fatigue Injectable 58% Emerging

Primary mitochondrial myopathy is human-studied but not as strong as the Barth syndrome evidence.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37268435/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

#### Human evidence

MMPOWER-3 tested elamipretide in primary mitochondrial myopathy, with efficacy and safety results that require cautious interpretation.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37268435/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

#### Animal / mechanistic evidence

Mechanistic reviews connect elamipretide to cardiolipin and mitochondrial bioenergetics.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37268435/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

### ### Mitochondrial function and cellular energy Injectable 54% Emerging

Cellular-energy claims depend on mitochondrial disease biology, not broad wellness or anti-aging proof.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/38871974/>)

#### Human evidence

Human mitochondrial-disease studies support the cellular-energy discussion indirectly through disease-specific endpoints.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37268435/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

#### Animal / mechanistic evidence

Mechanism and tafazzin-model studies support mitochondrial morphology, mitophagy, and bioenergetic plausibility.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/38871974/>)

### ### Heart-failure mitochondrial function Injectable 30% Limited

Heart-failure support is a separate preclinical mitochondrial-function signal.[\[26\]](<https://pubmed.ncbi.nlm.nih.gov/26839394/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

#### Human evidence

Human heart-failure outcome evidence is not established in the cited literature.[\[26\]](<https://pubmed.ncbi.nlm.nih.gov/26839394/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

#### Animal / mechanistic evidence

A dog model of advanced heart failure reported improved left-ventricular and mitochondrial function after chronic elamipretide therapy.[\[26\]](<https://pubmed.ncbi.nlm.nih.gov/26839394/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

### ### Mitochondrial aging biology Injectable 24% Limited

Mitochondrial aging biology is a plausible mechanism bucket, not evidence of human anti-aging benefit.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/38871974/>)

#### Human evidence

Human anti-aging, longevity, or broad wellness outcomes are not established for SS-31/elamipretide.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37268435/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)

#### Animal / mechanistic evidence

Mechanistic reviews connect elamipretide to cardiolipin, mitochondrial bioenergetics, morphology, and stress adaptation, which explains the mitochondrial-aging rationale.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40294492/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/38871974/>)

## Evidence snapshot

### Overall confidence

Strong

80%

Elamipretide has strong disease-specific support for Barth syndrome. General mitochondrial wellness, fatigue, or anti-aging uses are much less settled.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

80%

### Human evidence

Strong

FORZINITY labeling supports elamipretide for improving muscle strength in Barth syndrome under accelerated approval. Broader mitochondrial uses do not inherit that confidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

34%

### Animal / preclinical

Limited

Cardiolipin and mitochondrial-membrane evidence directly support the Barth-syndrome rationale.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

80%

### Mechanism support

Strong

Elamipretide is designed to interact with cardiolipin, a phospholipid important for mitochondrial inner-membrane structure and respiratory-chain function. The mechanism aims to stabilize mitochondrial energy machinery under stress.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

## Forms & administration

Elamipretide has separate subcutaneous-injection and investigational eye-drop formulations. The eye solution and injectable vial differ in concentration, delivered amount and application schedule; each requires its own product-specific preparation and administration instructions.[\[12\]](<https://clinicaltrials.gov/study/NCT05168774>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/37923251/>)

Injectable Ophthalmic

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Subcutaneous protocols use 20-30 mg per day. A common starting dose is 20 mg.[\[12\]](<https://clinicaltrials.gov/study/NCT05168774>)

### Frequency

Usually taken once daily.[\[12\]](<https://clinicaltrials.gov/study/NCT05168774>)

### Timing Considerations

Morning is the usual timing.[\[12\]](<https://clinicaltrials.gov/study/NCT05168774>)

### Cycle Length

Treatment commonly runs 52 weeks.[\[12\]](<https://clinicaltrials.gov/study/NCT05168774>)

[Full SS-31 dosage guide](<https://pepflow.app/peptides/ss-31/dosage/>)

## What to expect

### Weeks 4-12

Injectable elamipretide outcomes in mitochondrial-disease contexts center on muscle strength, fatigue, walking capacity, and daily function.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>)

### Months

Injectable Barth-syndrome treatment may show gradual changes in disease-specific function, biomarkers, and confirmed strength outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>)

### After stopping

Mitochondrial-disease benefits may lessen after injectable elamipretide ends if the underlying disease process remains active.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>)

## Safety profile

SS-31 safety now includes Forzinity label data for Barth syndrome and a separate non-label mitochondrial-wellness context.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

### Common side effects

- Injection-site reactions [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- Skin rash [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- Eosinophil increase [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

### Cautions

- Serious hypersensitivity[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- Benzyl alcohol / neonates[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- Renal impairment[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- Non-label use[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

### What we don't know

Barth-syndrome label data do not settle safety for non-label mitochondrial wellness use, different doses, or unsupervised compounded products.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

## Who SS-31 is not for

Route-specific avoid and medical-review notes:

- **Use outside label without clinician oversight**

  Use outside label without clinician oversight warrants medical review or avoidance for SS-31.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)
- **Pregnancy or breastfeeding unless specifically supervised**

  Pregnancy or breastfeeding unless specifically supervised warrants medical review or avoidance for SS-31.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Mitochondrial stacks**

  CoQ10, NAD+ products, MOTS-c, or other mitochondrial supplements can blur fatigue, exercise, and symptom tracking; this is a mechanism-and-dose gap.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- **Renal-stress drugs**

  Nephrotoxic drugs or unstable renal medication regimens can make renal status and elamipretide tolerability harder to separate; this is a route-specific caution.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- **Allergy-treatment overlap**

  Antihistamines or corticosteroids can mask mild rash or hypersensitivity signals during early dosing; this is a route-specific caution.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, FORZINITY elamipretide has FDA accelerated approval for Barth syndrome only. Mitochondrial wellness, anti-aging, or compounded SS-31 use sits outside that label and should not be treated as FDA-approved.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Approved · FORZINITY elamipretide is FDA-approved under accelerated approval for Barth syndrome; mitochondrial wellness, anti-aging, or compounded SS-31 use is outside that label.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) | Not Listed · 503A compounding for SS-31 is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Approved

FORZINITY elamipretide is FDA-approved under accelerated approval for Barth syndrome; mitochondrial wellness, anti-aging, or compounded SS-31 use is outside that label.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>)

503A compounding

Not Listed

503A compounding for SS-31 is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved.[\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets.[\[18\]](<https://www.ema.europa.eu/en/medicines>) [\[19\]](<https://products.mhra.gov.uk/>) [\[20\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[21\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA does not list SS-31 here as S2 in the same way as GH or gonadotropins, but non-approved systemic, wellness, or compounded use can still require S0-style anti-doping review.[\[8\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

SS-31, now approved as elamipretide for Barth syndrome, is designed to interact with cardiolipin in the mitochondrial inner membrane. In practical terms, the mechanism aims to stabilize respiratory-chain structure and energy production under mitochondrial stress.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

Injectable delivery and disease context define the claim. The pathway is most meaningful in cardiolipin-related mitochondrial disease biology; it does not automatically translate into broad anti-aging, fatigue, athletic, or wellness benefits without indication-specific outcomes. The route and diagnosis narrow what the mitochondrial mechanism can reasonably imply.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

## Research gaps & open questions

What the current literature has not yet settled about SS-31:

01

The required confirmatory trial still needs to show that improved knee-muscle strength translates into real benefits such as easier standing, walking, or daily activity for people with Barth syndrome.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

02

Separate trials need to show whether elamipretide helps people with dry age-related macular degeneration, primary mitochondrial muscle disease, heart failure, or other conditions; Barth-syndrome approval does not answer those questions.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

03

Studies need to establish safety and usefulness in people outside the approved rare-disease population, including the effects of long-term daily exposure.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

## Common questions

### Is SS-31 FDA-approved?

Yes. FDA granted accelerated approval to FORZINITY elamipretide for Barth syndrome; that does not approve general mitochondrial wellness or anti-aging use.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

### Is SS-31 approved for anti-aging?

No. SS-31 is not FDA-approved for anti-aging; the U.S. approval and human outcomes are disease-specific for Barth syndrome.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

### Is elamipretide the same as SS-31?

Yes. Elamipretide is the drug name associated with SS-31; approved use is indication-specific, not a blanket mitochondrial wellness claim.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)

## Myths & misconceptions

### Myth

FDA approval means SS-31 is proven for all mitochondrial goals.

### Reality

Approval is for a specific disease setting and cannot be generalized automatically.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

### Myth

Mitochondrial support equals longevity benefit.

### Reality

Mitochondrial mechanism is not the same as proven lifespan or anti-aging outcome.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)

## History & discovery

SS-31, later developed as elamipretide, began as a mitochondria-targeted peptide aimed at cardiolipin and inner-membrane stress biology. Barth syndrome eventually became the clearest clinical path. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>)

Clinical trials and long-term extension data tied elamipretide to Barth syndrome, a cardiolipin-related mitochondrial disease. That moved SS-31 from broad mitochondrial interest into a defined indication.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>)

FDA accelerated approval for FORZINITY made the history disease-specific: approved elamipretide is a Barth syndrome therapy, not a blanket mitochondrial wellness or anti-aging product.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/38602181/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/33077895/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36400945/>) [\[13\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>)

## Published research 26 citations

- [\[1\] **Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.** Genet Med, 2024 Jul. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38602181/>)
- [\[2\] **A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.** Genet Med, 2021 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33077895/>)
- [\[3\] **Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.** Sci Rep, 2022 Nov 18. animal.](<https://pubmed.ncbi.nlm.nih.gov/36400945/>)
- [\[4\] **Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.** Mol Genet Metab, 2025 Sep-Oct. review.](<https://pubmed.ncbi.nlm.nih.gov/40816230/>)
- [\[5\] **SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.** Sci Rep, 2024 Jun 13. animal.](<https://pubmed.ncbi.nlm.nih.gov/38871974/>)
- [\[6\] **Drugs@FDA/openFDA query for SS-31** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22SS-31%22&limit=1>)
- [\[7\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[8\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[9\] **Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.** Ophthalmology, 2024 Apr. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37923251/>)
- [\[10\] **Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.** Neurology, 2023 Jul 18. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37268435/>)
- [\[11\] **Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects.** Biomed Pharmacother, 2025 Jun. review.](<https://pubmed.ncbi.nlm.nih.gov/40294492/>)
- [\[12\] **FRDA investigator-initiated study with elamipretide** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05168774>)
- [\[13\] **FORZINITY elamipretide prescribing information** U.S. Food and Drug Administration, 2025. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf>)
- [\[14\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[15\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[16\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[17\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[18\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[19\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[20\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[21\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[22\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[23\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[24\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[25\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)
- [\[26\] **Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.** Circ Heart Fail, 2016 Feb. animal.](<https://pubmed.ncbi.nlm.nih.gov/26839394/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Mitochondrial peptide

**Tier**

A

**Evidence**

80% Strong

**Safety**

Well-Studied

**FDA status**

Approved

**Injectable 503A**

Not Listed

**Citations**

[26 citations](<https://pepflow.app/peptides/ss-31/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Barth syndrome
- Primary mitochondrial myopathy and fatigue
- Mitochondrial function and cellular energy
- Heart-failure mitochondrial function
- Mitochondrial aging biology

### Common side effects

- Injection-site reactions
- Skin rash
- Eosinophil increase

### Also known as

- Elamipretide
- Bendavia
- MTP-131
- Forzinity

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [SS-31 dosage guide](<https://pepflow.app/peptides/ss-31/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
